Gyre Therapeutics (GYRE) Competitors

$6.34 0.00 (0.00%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$6.33 -0.01 (-0.16%)

As of 07/14/2026 04:40 PM Eastern

GYRE vs. ELVN, IRON, TARS, KLRA, and VERA

Should you buy Gyre Therapeutics stock or one of its competitors? MarketBeat compares Gyre Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gyre Therapeutics include Enliven Therapeutics (ELVN), Disc Medicine (IRON), Tarsus Pharmaceuticals (TARS), Kailera Therapeutics (KLRA), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry.

How does Gyre Therapeutics compare to Enliven Therapeutics?

Enliven Therapeutics (NASDAQ:ELVN) and Gyre Therapeutics (NASDAQ:GYRE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Enliven Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market.

Gyre Therapeutics has higher revenue and earnings than Enliven Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Enliven Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Gyre Therapeutics	$116.59M	6.06	$5.03M	-$0.09	N/A

In the previous week, Enliven Therapeutics had 12 more articles in the media than Gyre Therapeutics. MarketBeat recorded 14 mentions for Enliven Therapeutics and 2 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.94 beat Enliven Therapeutics' score of 1.02 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Enliven Therapeutics	Positive
Gyre Therapeutics	Very Positive

Enliven Therapeutics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Gyre Therapeutics	-5.44%	3.13%	2.67%

Enliven Therapeutics presently has a consensus price target of $69.17, indicating a potential upside of 33.71%. Gyre Therapeutics has a consensus price target of $17.00, indicating a potential upside of 168.14%. Given Gyre Therapeutics' higher probable upside, analysts plainly believe Gyre Therapeutics is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Gyre Therapeutics beats Enliven Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Gyre Therapeutics compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and Gyre Therapeutics (NASDAQ:GYRE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings, media sentiment and risk.

Gyre Therapeutics has higher revenue and earnings than Disc Medicine. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A
Gyre Therapeutics	$116.59M	6.06	$5.03M	-$0.09	N/A

Disc Medicine currently has a consensus target price of $104.44, indicating a potential upside of 39.24%. Gyre Therapeutics has a consensus target price of $17.00, indicating a potential upside of 168.14%. Given Gyre Therapeutics' higher possible upside, analysts clearly believe Gyre Therapeutics is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Disc Medicine has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the broader market.

In the previous week, Disc Medicine had 7 more articles in the media than Gyre Therapeutics. MarketBeat recorded 9 mentions for Disc Medicine and 2 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.94 beat Disc Medicine's score of 0.26 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Disc Medicine	Neutral
Gyre Therapeutics	Very Positive

83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 3.8% of Disc Medicine shares are owned by company insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Disc Medicine has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-36.94%	-33.88%
Gyre Therapeutics	-5.44%	3.13%	2.67%

Summary

Gyre Therapeutics beats Disc Medicine on 9 of the 15 factors compared between the two stocks.

How does Gyre Therapeutics compare to Tarsus Pharmaceuticals?

Gyre Therapeutics (NASDAQ:GYRE) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Gyre Therapeutics has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

In the previous week, Tarsus Pharmaceuticals had 12 more articles in the media than Gyre Therapeutics. MarketBeat recorded 14 mentions for Tarsus Pharmaceuticals and 2 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.94 beat Tarsus Pharmaceuticals' score of 0.33 indicating that Gyre Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Gyre Therapeutics	Very Positive
Tarsus Pharmaceuticals	Neutral

Gyre Therapeutics has a net margin of -5.44% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Gyre Therapeutics' return on equity of 3.13% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Gyre Therapeutics currently has a consensus price target of $17.00, suggesting a potential upside of 168.14%. Tarsus Pharmaceuticals has a consensus price target of $90.67, suggesting a potential upside of 61.59%. Given Gyre Therapeutics' higher possible upside, equities analysts plainly believe Gyre Therapeutics is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Gyre Therapeutics has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	6.06	$5.03M	-$0.09	N/A
Tarsus Pharmaceuticals	$451.36M	5.35	-$66.42M	-$1.14	N/A

Summary

Gyre Therapeutics beats Tarsus Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Gyre Therapeutics compare to Kailera Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Kailera Therapeutics (NASDAQ:KLRA) are both pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

In the previous week, Kailera Therapeutics had 3 more articles in the media than Gyre Therapeutics. MarketBeat recorded 5 mentions for Kailera Therapeutics and 2 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.94 beat Kailera Therapeutics' score of 0.43 indicating that Gyre Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Gyre Therapeutics	Very Positive
Kailera Therapeutics	Neutral

Gyre Therapeutics presently has a consensus target price of $17.00, suggesting a potential upside of 168.14%. Kailera Therapeutics has a consensus target price of $42.75, suggesting a potential upside of 124.88%. Given Gyre Therapeutics' higher probable upside, equities research analysts clearly believe Gyre Therapeutics is more favorable than Kailera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Kailera Therapeutics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Kailera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Kailera Therapeutics	N/A	N/A	N/A

Gyre Therapeutics has higher revenue and earnings than Kailera Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	6.06	$5.03M	-$0.09	N/A
Kailera Therapeutics	N/A	N/A	N/A	-$3.65 thousand	N/A

24.0% of Gyre Therapeutics shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Gyre Therapeutics beats Kailera Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Gyre Therapeutics compare to Vera Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Vera Therapeutics (NASDAQ:VERA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

Gyre Therapeutics has higher revenue and earnings than Vera Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	6.06	$5.03M	-$0.09	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

24.0% of Gyre Therapeutics shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 9.5% of Gyre Therapeutics shares are owned by insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Gyre Therapeutics currently has a consensus price target of $17.00, suggesting a potential upside of 168.14%. Vera Therapeutics has a consensus price target of $84.58, suggesting a potential upside of 96.11%. Given Gyre Therapeutics' higher possible upside, equities analysts clearly believe Gyre Therapeutics is more favorable than Vera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

In the previous week, Vera Therapeutics had 24 more articles in the media than Gyre Therapeutics. MarketBeat recorded 26 mentions for Vera Therapeutics and 2 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 1.94 beat Vera Therapeutics' score of 0.60 indicating that Gyre Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Gyre Therapeutics	Very Positive
Vera Therapeutics	Positive

Vera Therapeutics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-5.44%	3.13%	2.67%
Vera Therapeutics	N/A	-74.86%	-60.18%

Gyre Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

Summary

Gyre Therapeutics beats Vera Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Gyre Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GYRE vs. The Competition

Export

Metric	Gyre Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$706.84M	$3.68B	$6.85B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-70.44	20.98	27.01	24.38
Price / Sales	6.06	311.11	522.34	92.57
Price / Cash	28.53	143.66	48.59	59.36
Price / Book	4.28	8.54	10.80	6.33
Net Income	$5.03M	$23.83M	$3.59B	$331.02M
7 Day Performance	-7.58%	-2.77%	-1.49%	-0.33%
1 Month Performance	8.19%	5.85%	2.79%	-1.29%
1 Year Performance	-11.45%	52.15%	28.56%	21.30%

Gyre Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GYRE Gyre Therapeutics	2.5165 of 5 stars	$6.34 flat	$17.00 +168.1%	-16.7%	$706.84M	$116.59M	N/A	40
ELVN Enliven Therapeutics	3.3939 of 5 stars	$50.92 +1.8%	$67.83 +33.2%	+124.9%	$3.05B	N/A	N/A	50	Positive News Analyst Revision
IRON Disc Medicine	2.4727 of 5 stars	$79.76 +3.6%	$104.44 +30.9%	+29.9%	$2.94B	N/A	N/A	30	Insider Trade
TARS Tarsus Pharmaceuticals	2.7609 of 5 stars	$70.55 +5.2%	$90.67 +28.5%	+35.1%	$2.88B	$451.36M	N/A	50	Analyst Downgrade
KLRA Kailera Therapeutics	4.1661 of 5 stars	$22.24 -4.5%	$42.75 +92.2%	N/A	$2.88B	N/A	N/A	145	Short Interest Increase

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GYRE) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gyre Therapeutics (GYRE) Competitors

GYRE vs. ELVN, IRON, TARS, KLRA, and VERA

How does Gyre Therapeutics compare to Enliven Therapeutics?

Summary

How does Gyre Therapeutics compare to Disc Medicine?

Summary

How does Gyre Therapeutics compare to Tarsus Pharmaceuticals?

Summary

How does Gyre Therapeutics compare to Kailera Therapeutics?

Summary

How does Gyre Therapeutics compare to Vera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GYRE vs. The Competition

Gyre Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gyre Therapeutics (GYRE) Competitors

GYRE vs. ELVN, IRON, TARS, KLRA, and VERA

How does Gyre Therapeutics compare to Enliven Therapeutics?

Do institutionals & insiders believe in ELVN or GYRE?

Which has more risk & volatility, ELVN or GYRE?

Which has stronger valuation & earnings, ELVN or GYRE?

Does the media prefer ELVN or GYRE?

Is ELVN or GYRE more profitable?

Do analysts prefer ELVN or GYRE?

Summary

How does Gyre Therapeutics compare to Disc Medicine?

Which has better earnings and valuation, IRON or GYRE?

Do analysts prefer IRON or GYRE?

Which has more volatility & risk, IRON or GYRE?

Does the media prefer IRON or GYRE?

Do insiders & institutionals believe in IRON or GYRE?

Is IRON or GYRE more profitable?

Summary

How does Gyre Therapeutics compare to Tarsus Pharmaceuticals?

Which has more volatility and risk, GYRE or TARS?

Does the media refer more to GYRE or TARS?

Is GYRE or TARS more profitable?

Do insiders and institutionals believe in GYRE or TARS?

Do analysts prefer GYRE or TARS?

Which has stronger valuation and earnings, GYRE or TARS?

Summary

How does Gyre Therapeutics compare to Kailera Therapeutics?

Does the media refer more to GYRE or KLRA?

Do analysts prefer GYRE or KLRA?

Is GYRE or KLRA more profitable?

Which has better earnings & valuation, GYRE or KLRA?

Do insiders & institutionals believe in GYRE or KLRA?

Summary

How does Gyre Therapeutics compare to Vera Therapeutics?

Which has higher valuation & earnings, GYRE or VERA?

Do institutionals & insiders hold more shares of GYRE or VERA?

Do analysts rate GYRE or VERA?

Does the media favor GYRE or VERA?

Is GYRE or VERA more profitable?

Which has more volatility and risk, GYRE or VERA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GYRE vs. The Competition

Gyre Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools